Biotechnology company 4basebio PLC (AIM: 4BB) on Wednesday announced the provision of its HQ synthetic DNA to a Tier 1 Pharma Company for late preclinical studies in an mRNA vaccine program. Following a successful opDNA evaluation study, the client has progressed to HQ opDNA. GMP grade material supply for clinical trials is expected in Q3.

Based in Cambridge, UK, 4basebio specialises in synthetic DNA products and non-viral, cell-targeting nucleic acid delivery platforms.

With a focus on advancing therapy medicinal products (ATMPs), the company aims to lead the market in manufacturing and supplying high-quality synthetic DNA products for research, therapeutic and pharmacological applications.

Additionally, the company develops target-specific non-viral vectors for efficient payload delivery in patients, including GMP-compliant DNA starting materials suitable for AAV viral vector production, mRNA vaccine and therapeutics production.